## ICMJE DISCLOSURE FORM

Please save/export the filled in form as PDF before submitting it to Ugeskrift for Læger or Danish Medical Journal.

| Date                     | <b>e</b> : 28. maj 2021  |   |   |
|--------------------------|--|---|---|
|                          | r name: Birgit Alsbjerg  |   |   |
|                          | 3 3 3  | isteret Reproduktions Tekno   | logi resulterer i større succes og færre komplikationer   |
|                          | nuscript number (if known  |   | resulterer i større succes og tærre komplikationer  |
| are re<br>third<br>comr  | elated to the content of yo<br>parties whose interests ma  | ur manuscript. "Related"<br>ay be affected by the cont<br>nd does not necessarily in  | relationships/activities/interests listed below that<br>means any relation with for-profit or not-for-profit<br>tent of the manuscript. Disclosure represents a<br>dicate a bias. If you are in doubt about whether to<br>bu do so. |
|                          | ollowing questions apply to<br>uscript only.   | o the author's relationship   | os/activities/interests as they relate to the <u>current</u>  |
| perta<br>antih<br>In ite | ins to the epidemiology of ypertensive medication, ev  | hypertension, you should<br>yen if that medication is n<br>port for the work reported   | defined broadly. For example, if your manuscript declare all relationships with manufacturers of ot mentioned in the manuscript.  d in this manuscript without time limit. For all months.  |
|                          |  | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed)  | Specifications/Comments (e.g., if payments were made to you or to your institution)   |
| Time                     | e frame: Since the initial plan  |   |   |
| 1                        | All support for the present<br>manuscript (e.g., funding,<br>provision of study<br>materials, medical writing,<br>article processing charges,<br>etc.) | ⊠ None  |   |
|                          | No time limit for this item.   |   |   |
|                          |  |   | Click TAB in last row to add extra rows   |
| Time                     | e frame: past 36 months  |   |   |
| 2                        | Grants or contracts from any entity (if not indicated in item #1 above).   | None  |   |
| 3                        | Royalties or licenses  | None     Non |   |
|                          | ·  |   |   |

| 4  | Consulting fees  | □ None  |                        |  |  |
|----|--|---|------------------------|--|--|
|    |  |   |                        |  |  |
| Г  |  |   |                        |  |  |
| 5  | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | Gedeon Richter Merck  | Honoraria for lectures |  |  |
| 6  | Payment for expert testimony   | ⊠ None  |                        |  |  |
| 7  | Support for attending meetings and/or travel   | ⊠ None  |                        |  |  |
| 8  | Patents planned, issued or pending   | None  |                        |  |  |
| 9  | Participation on a Data<br>Safety Monitoring Board<br>or Advisory Board                                      |   |                        |  |  |
|    |  |   |                        |  |  |
| 10 | Leadership or fiduciary  | ⊠ None  |                        |  |  |
|    | role in other board,<br>society, committee or<br>advocacy group, paid or<br>unpaid                           |   |                        |  |  |
|    |  |   |                        |  |  |
|    |  |   |                        |  |  |
| 11 | Stock or stock options   | None     Non |                        |  |  |
|    |  |   |                        |  |  |
| 12 | Receipt of equipment,<br>materials, drugs, medical<br>writing, gifts or other<br>services                    | None  |                        |  |  |
|    |  |   |                        |  |  |
| 13 | Other financial or non-<br>financial interests   | None     Non |                        |  |  |
|    |  |   |                        |  |  |

Please place an "X" next to the following statement to indicate your agreement:

 $\boxtimes$  I certify that I have answered every question and have not altered the wording of any of the questions on this form.

## IMPORTANT for Ugeskrift for Læger & Danish Medical Journal

Please save/export the filled in form as PDF before submitting it to Ugeskrift for Læger or Danish Medical Journal.

## ICMJE DISCLOSURE FORM

Please save/export the filled in form as PDF before submitting it to Ugeskrift for Læger or Danish Medical Journal.

| Date                              | <b>2</b> : 28. maj 2021   |   |  |
|-----------------------------------|---|---|--|
| You                               | r name: Peter Humaidan  | l:  |  |
| Mar                               | nuscript titlNye metoder Ass  | isteret Reproduktions Tekno   | ologi resulterer i større succes og færre komplikationer   |
|                                   | nuscript number (if known)  |   |  |
|                                   |   | ,   |  |
| are rethird commist a The formant | elated to the content of yo parties whose interests manitment to transparency are relationship/activity/interectionship/activity/interectionship questions apply to ascript only. | ur manuscript. "Related" ay be affected by the control does not necessarily in est, it is preferable that you the author's relationship | os/activities/interests as they relate to the <u>current</u>   |
| oerta                             | ins to the epidemiology of  | hypertension, you should  | defined broadly. For example, if your manuscript declare all relationships with manufacturers of ot mentioned in the manuscript. |
|                                   | m #1 below, report all suppitems, the time frame for  | •   | d in this manuscript without time limit. For all months.   |
|                                   |   | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as   | Specifications/Comments (e.g., if payments were made to you or to your institution)  |
|                                   |   | needed)   |  |
|                                   | e frame: Since the initial plan   |   |  |
| 1                                 | All support for the present   | None  |  |
|                                   | manuscript (e.g., funding, provision of study   |   |  |
|                                   | materials, medical writing,   |   |  |
|                                   | article processing charges,   |   |  |
|                                   | etc.)   |   |  |
|                                   | No time limit for this  |   |  |
|                                   | No time limit for this item.  |   |  |
|                                   | itom.   |   |  |
|                                   |   |   | Click TAB in last row to add extra rows  |
| Time                              | e frame: past 36 months   |   |  |
| ე I                               | Crants or contrasts from  | □None   |  |
| 2                                 | Grants or contracts from any entity (if not indicated in item #1 above).  | ☐ <b>None</b> Unrestricted research   |  |
|                                   |   | grants from Merck,<br>Ferring, Gedeon Richter<br>and IBSA   |  |
|                                   |   |   |  |
| 3                                 | Royalties or licenses   | ⊠ None  |  |

| 4  | Consulting fees   | None     Non |
|----|---|---|
|    |   |   |
|    |   |   |
| 5  | Payment or honoraria for lectures, presentations, speakers bureaus,   | □ None  |
|    |   | Honoraria for lectures from Merck, and  |
|    | manuscript writing or   | Gedeon Richter  |
|    | educational events  |   |
|    |   |   |
| 6  | Daymont for expert  | N None  |
| 6  | Payment for expert testimony  |   |
|    | ,   |   |
| 7  | Support for attending   | ⊠ None  |
|    | meetings and/or travel  |   |
|    |   |   |
| 8  | Patents planned, issued or  | None     Non |
|    | pending   |   |
|    |   |   |
| 9  | Participation on a Data<br>Safety Monitoring Board  | ⊠ None  |
|    | or Advisory Board   |   |
| 10 | Leadership or fiduciary<br>role in other board,<br>society, committee or<br>advocacy group, paid or<br>unpaid | M None  |
| 10 |   | None     Non |
|    |   |   |
|    |   |   |
|    |   |   |
| 11 | Stock or stock options  | ⊠ None  |
|    |   |   |
| 12 | Receipt of equipment,<br>materials, drugs, medical<br>writing, gifts or other<br>services                     | ⊠ None  |
| 12 |   | A NOTE  |
|    |   |   |
|    |   |   |
| 13 | Other financial or non-<br>financial interests  | ⊠ None  |
|    |   |   |
|    |   |   |

Please place an "X" next to the following statement to indicate your agreement:

 ${f f Z}$  I certify that I have answered every question and have not altered the wording of any of the questions on this form.

| IMPORTANT for Ugeskrift for Læger & Danish Medical Journal Please save/export the filled in form as PDF before submitting it to Ugeskrift for Læger or Danish Medical Journal. |             |  |  |  |
|--|-------------|--|--|--|
|  |             |  |  |  |
|  |             |  |  |  |
|  |             |  |  |  |
|  |             |  |  |  |
|  |             |  |  |  |
|  |             |  |  |  |
|  |             |  |  |  |
|  |             |  |  |  |
|  |             |  |  |  |
|  |             |  |  |  |
|  |             |  |  |  |
|  |             |  |  |  |
|  |             |  |  |  |
| ICMJE Disclosure Form (Feb2021): http://icmje.org  | Page 3 of 3 |  |  |  |